Evidence map›Paper›PMID 31708478›Full record

ArticleStem cell reports2019

Reprogramming of Fibroblasts to Oligodendrocyte Progenitor-like Cells Using CRISPR/Cas9-Based Synthetic Transcription Factors.

Mantas Matjusaitis, Laura J Wagstaff, Andrea Martella, Bart Baranowski, Carla Blin, Sabine Gogolok, Anna Williams, Steven M Pollard

Open access · goldAbstract read
In one paragraph

Article in Stem cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Overexpression ofCurrent issues in molecular biology · 2023
    Article
  5. Review
  6. Review
  7. Article
  8. EditingInternational journal of molecular sciences · 2021
    Review
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mantas MatjusaitisMRC Centre for Regenerative Medicine and Edinburgh Cancer Research UK Centre, University of Edinburgh, 5 Little France Drive, Edinburgh EH16 4UU, UK.
Laura J WagstaffMRC Centre for Regenerative Medicine and Edinburgh Cancer Research UK Centre, University of Edinburgh, 5 Little France Drive, Edinburgh EH16 4UU, UK.
Andrea MartellaMRC Centre for Regenerative Medicine and Edinburgh Cancer Research UK Centre, University of Edinburgh, 5 Little France Drive, Edinburgh EH16 4UU, UK.
Bart BaranowskiMRC Centre for Regenerative Medicine and Edinburgh Cancer Research UK Centre, University of Edinburgh, 5 Little France Drive, Edinburgh EH16 4UU, UK.
Carla BlinMRC Centre for Regenerative Medicine and Edinburgh Cancer Research UK Centre, University of Edinburgh, 5 Little France Drive, Edinburgh EH16 4UU, UK.
Sabine GogolokMRC Centre for Regenerative Medicine and Edinburgh Cancer Research UK Centre, University of Edinburgh, 5 Little France Drive, Edinburgh EH16 4UU, UK.
Anna WilliamsMRC Centre for Regenerative Medicine and Edinburgh Cancer Research UK Centre, University of Edinburgh, 5 Little France Drive, Edinburgh EH16 4UU, UK.
Steven M PollardMRC Centre for Regenerative Medicine and Edinburgh Cancer Research UK Centre, University of Edinburgh, 5 Little France Drive, Edinburgh EH16 4UU, UK. Electronic address: steven.pollard@ed.ac.uk.
Edinburgh Cancer Research · GBUniversity of Edinburgh · GBMRC Centre for Regenerative Medicine · GB

Funding

Biotechnology and Biological Sciences Research Council BB/M018040/1Cancer Research UK 17368Cancer Research UK 21992Cancer Research UK A17368Medical Research Council MR/K017047/1Medical Research Council MR/P016022/1Medical Research Council MR/S035915/1Medical Research Council MR/T015594/1
6 · The paper itself

Abstract

Cell lineage reprogramming via transgene overexpression of key master regulatory transcription factors has been well documented. However, the poor efficiency and lack of fidelity of this approach is problematic. Synthetic transcription factors (sTFs)-built from the repurposed CRISPR/Cas9 system-can activate endogenous target genes to direct differentiation or trigger lineage reprogramming. Here we explored whether sTFs could be used to steer mouse neural stem cells and mouse embryonic fibroblasts toward the oligodendrocyte lineage. We developed a non-viral modular expression system to enable stable multiplex delivery of pools of sTFs capable of transcriptional activation of three key oligodendrocyte lineage master regulatory genes (Sox10, Olig2, and Nkx6-2). Delivery of these sTFs could enhance neural stem cell differentiation and initiated mouse embryonic fibroblast direct reprograming toward oligodendrocyte progenitor-like cells. Our findings demonstrate the value of sTFs as tools for activating endogenous genes and directing mammalian cell-type identity.

Indexed as

CRISPR-Cas SystemsAnimalsBiomarkersCellular ReprogrammingFibroblastsGene EditingGene ExpressionMiceOligodendrocyte Precursor CellsOligodendrogliaRNA, Guide, CRISPR-Cas SystemsTranscriptional ActivationTranscription FactorsBiomarkersRNA, Guide, CRISPR-Cas SystemsTranscription FactorsCRISPR-Cas9dCas9designer transcription factorslineage conversionmouse embryonic fibroblastsneural stem cellsoligodendrocyte

Identifiers

PMID31708478
PMCPMC6915844
OpenAlexW2987095667

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.